RespireRx Pharmaceuticals Inc (RSPI)

[K-G]

Bladerunner,
I don't think I've seen anyone suggest that any in-licensed program would be positive. Most of the in-licensed posts to this board have obviously been negative, but I think that we have just not been creative enough to figure out what types of in-licensing might occur to assess whether all scenarios would have a negative impact. Without being especially knowlegable on the the subject, I think I can imagine some scenarios for in-licensing that would provide a positive impact, even with the limited funds the company currently has available. For example: in-licensing a compound that has already met significant milestones for some indication, but is licensed for an orphan indication in which the compound owner has no interest; in-licensing a compound for a neurological indication that your staff is familiar, and can be managed with less impact than for a completely new indication; in-licensing a compound that has failed to be effacious within some dosing limits, but looks like it could be effacious at much lower doses when combined with an ampakine; arranging a back-end licensing agreement where payments are only due after success. I'm sure there are many possibilities that I can't imagine. I'm also guessing that the Cortex folks are very worried about spending their money wisely, and are only considering options that require low costs - especially if they have evidence that a compound has significant potential and have an opportunity to obtain the rights before someone else does.